Wipfli Financial Advisors LLC acquired a new position in shares of The Chemours Company (NYSE:CC – Get Rating) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,574 shares of the specialty chemicals company’s stock, valued at approximately $63,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in CC. Asset Management One Co. Ltd. acquired a new stake in shares of Chemours in the second quarter valued at $25,000. CNB Bank acquired a new stake in Chemours in the second quarter worth about $25,000. Trust Co. of Vermont acquired a new stake in Chemours in the second quarter worth about $35,000. Ellevest Inc. increased its position in Chemours by 34,325.0% in the second quarter. Ellevest Inc. now owns 1,377 shares of the specialty chemicals company’s stock worth $44,000 after purchasing an additional 1,373 shares during the period. Finally, GPS Wealth Strategies Group LLC increased its position in Chemours by 82.9% in the second quarter. GPS Wealth Strategies Group LLC now owns 1,655 shares of the specialty chemicals company’s stock worth $53,000 after purchasing an additional 750 shares during the period. 71.89% of the stock is currently owned by institutional investors and hedge funds.
Chemours Stock Up 0.9 %
NYSE:CC opened at $33.58 on Friday. The firm has a market capitalization of $5.07 billion, a price-to-earnings ratio of 5.99, a price-to-earnings-growth ratio of 0.66 and a beta of 1.84. The Chemours Company has a twelve month low of $22.56 and a twelve month high of $44.95. The stock’s 50 day moving average price is $31.47 and its two-hundred day moving average price is $31.57. The company has a quick ratio of 1.14, a current ratio of 1.82 and a debt-to-equity ratio of 2.73.
Chemours Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Thursday, December 15th. Stockholders of record on Tuesday, November 15th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Monday, November 14th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 2.98%. Chemours’s payout ratio is 17.83%.
Analyst Ratings Changes
A number of analysts recently commented on the company. Credit Suisse Group initiated coverage on Chemours in a research report on Tuesday, November 1st. They issued an “underperform” rating and a $24.00 price objective for the company. Argus cut Chemours from a “buy” rating to a “hold” rating in a report on Wednesday, October 5th. StockNews.com upgraded Chemours from a “hold” rating to a “buy” rating in a report on Saturday. BMO Capital Markets cut their price objective on Chemours from $46.00 to $41.00 and set an “outperform” rating on the stock in a report on Thursday, October 27th. Finally, The Goldman Sachs Group initiated coverage on Chemours in a report on Thursday, October 13th. They set a “neutral” rating and a $30.00 price objective on the stock. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $32.90.
The Chemours Co is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial.
- Get a free copy of the StockNews.com research report on Chemours (CC)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here’s Why
- Carvana Stock Rally, Here’s What You Need to Know
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.